理解市場 | 康方生物漲超 8% 依沃西 HARMONi-6 研究結果將於《柳葉刀》和 ESMO LBA 同步發表
Akeso's stock price rose by more than 8%, with an increase of 6.97% as of the time of writing, reported at HKD 130.5, with a transaction volume of HKD 749 million. The company announced that the results of the Phase III clinical study of its dual-specific antibody new drug, Ivorocimab, will be published in 2025 in The Lancet and at the European Society for Medical Oncology (ESMO) conference, with a verbal presentation by Professor Lu Shun, showcasing its comparative results with PD-1 combined chemotherapy
According to Zhitong Finance APP, AKESO (09926) rose over 8%, and as of the time of writing, it increased by 6.97%, reaching HKD 130.5, with a transaction volume of HKD 749 million.
In terms of news, according to AKESO's official WeChat account, on October 16, the results of the registrational Phase III clinical study (AK112-306/HARMONi-6) comparing the self-developed global first-in-class bispecific antibody drug Ivosidenib (PD-1/VEGF bispecific antibody) combined with chemotherapy against Tislelizumab combined with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) have been accepted by the prestigious international medical journal The Lancet and will be published during the European Society for Medical Oncology (ESMO 2025) conference in 2025, with significant results set to shine on the global scientific research stage.
It is reported that the research results have successfully been selected for the 2025 ESMO Late-Breaking Abstract (LBA) and will be presented in a verbal report at the most anticipated Presidential Symposium of the ESMO annual meeting by the principal investigator, Professor Lu Shun, Director of the Oncology Department at Shanghai Chest Hospital, showcasing the outstanding results of the head-to-head Phase III clinical study of Ivosidenib combined with chemotherapy versus the currently most widely used PD-1 combined chemotherapy regimen in tumor immunotherapy to the global oncology community
